Ann Dermatol.  2013 Aug;25(3):273-277. 10.5021/ad.2013.25.3.273.

Total Serum Oxidant/Antioxidant Status and Arylesterase Activity in Recurrent Aphthous Stomatitis

• Akoglu G
• Metin A
• Kilinc F
• Pektas SD
• Isikoglu S
• Akbas A
• Sener S

• KMID: 2265864
• DOI: http://doi.org/10.5021/ad.2013.25.3.273

Abstract

BACKGROUND
Recurrent aphthous stomatitis (RAS) is a chronic relapsing inflammatory disorder of the oral mucosa with unknown etiology. Oxidative stress (OS) is suggested to play a main role in the etiopathogenesis in RAS.
OBJECTIVE
In this study, we hypothesize that a systemic OS is present in patients with RAS.
METHODS
Forty-four patients with active RAS lesions and 38 healthy controls were being included in the study. Serum total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), and paraoxonase 1 arylesterase (ARES) activity were being determined.
RESULTS
RAS patients had significantly lower TAS levels and higher TOS and OSI values than controls. The patients had a lower ARES activity when compared to healthy controls. No correlations were observed between OS parameters and age, gender, duration of disease or frequency of RAS attacks per month.
CONCLUSION
A systemic OS is determined with an imbalance in oxidant/antioxidant status and lower ARES activity in RAS. Systemic OS may have an important role in the pathogenesis of RAS formation.

Keyword

Arylesterase activity; Oxidative stress; Recurrent aphthous stomatitis; Total antioxidant status; Total oxidant status

MeSH Terms

Aryldialkylphosphatase
Carboxylic Ester Hydrolases
Humans
Mouth Mucosa
Oxidative Stress
Stomatitis, Aphthous
Aryldialkylphosphatase
Carboxylic Ester Hydrolases

Reference

1. Shashy RG, Ridley MB. Aphthous ulcers: a difficult clinical entity. Am J Otolaryngol. 2000; 21:389–393.

2. Preeti L, Magesh K, Rajkumar K, Karthik R. Recurrent aphthous stomatitis. J Oral Maxillofac Pathol. 2011; 15:252–256.

3. Huling LB, Baccaglini L, Choquette L, Feinn RS, Lalla RV. Effect of stressful life events on the onset and duration of recurrent aphthous stomatitis. J Oral Pathol Med. 2012; 41:149–152.

4. Baccaglini L, Lalla RV, Bruce AJ, Sartori-Valinotti JC, Latortue MC, Carrozzo M, et al. Urban legends: recurrent aphthous stomatitis. Oral Dis. 2011; 17:755–770.

5. Porter SR, Scully C, Pedersen A. Recurrent aphthous stomatitis. Crit Rev Oral Biol Med. 1998; 9:306–321.

6. Lewkowicz N, Lewkowicz P, Kurnatowska A, Banasik M, Glowacka E, Cedzyński M, et al. Innate immune system is implicated in recurrent aphthous ulcer pathogenesis. J Oral Pathol Med. 2003; 32:475–481.

7. Vertuani S, Angusti A, Manfredini S. The antioxidants and pro-antioxidants network: an overview. Curr Pharm Des. 2004; 10:1677–1694.

8. Cağlayan F, Miloglu O, Altun O, Erel O, Yilmaz AB. Oxidative stress and myeloperoxidase levels in saliva of patients with recurrent aphthous stomatitis. Oral Dis. 2008; 14:700–704.

9. Momen-Beitollahi J, Mansourian A, Momen-Heravi F, Amanlou M, Obradov S, Sahebjamee M. Assessment of salivary and serum antioxidant status in patients with recurrent aphthous stomatitis. Med Oral Patol Oral Cir Bucal. 2010; 15:e557–e561.

10. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol. 2001; 54:176–186.

11. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med. 1991; 91:14S–22S.

12. Sardesai VM. Role of antioxidants in health maintenance. Nutr Clin Pract. 1995; 10:19–25.

13. Cimen MY, Kaya TI, Eskandari G, Tursen U, Ikizoglu G, Atik U. Oxidant/antioxidant status in patients with recurrent aphthous stomatitis. Clin Exp Dermatol. 2003; 28:647–650.

14. Gunduz K, Ozturk G, Sozmen EY. Erythrocyte superoxide dismutase, catalase activities and plasma nitrite and nitrate levels in patients with Behçet disease and recurrent aphthous stomatitis. Clin Exp Dermatol. 2004; 29:176–179.

15. Karincaoglu Y, Batcioglu K, Erdem T, Esrefoglu M, Genc M. The levels of plasma and salivary antioxidants in the patient with recurrent aphthous stomatitis. J Oral Pathol Med. 2005; 34:7–12.

16. Sepici-Dinçel A, Ozkan Y, Yardim-Akaydin S, Kaymak-Karataş G, Onder M, Simşek B. The association between total antioxidant status and oxidative stress in Behçet's disease. Rheumatol Int. 2006; 26:1005–1009.

17. Arikan S, Durusoy C, Akalin N, Haberal A, Seckin D. Oxidant/antioxidant status in recurrent aphthous stomatitis. Oral Dis. 2009; 15:512–515.

18. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol. 2004; 286:R431–R444.

19. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38:1103–1111.

20. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004; 37:277–285.

21. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993; 104:129–135.

22. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol. 2000; 11:383–388.

23. Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Sala J, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab. 2003; 88:5422–5426.

24. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis. 2001; 155:229–235.

25. Esen C, Alkan BA, Kırnap M, Akgül O, Işkoğlu S, Erel O. The effects of chronic periodontitis and rheumatoid arthritis on serum and gingival crevicular fluid total antioxidant/oxidant status and oxidative stress index. J Periodontol. 2012; 83:773–779.

26. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000; 20:2441–2447.

27. James RW. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med. 2006; 44:1052–1059.